Vol. 19/No. 20 | OncologyLive

CD22 Emerges as CAR T-Cell Therapy Target

October 17, 2018

Although CD19 has proved to be an attractive and effective target for chimeric antigen receptor T-cell therapies in hematologic malignancies, a significant subset of patients treated with this groundbreaking form of immunotherapy eventually relapse.

Step Therapy Policy Alarms Cancer Leaders

October 16, 2018

A policy change that allows step therapy provisions in Medicare Advantage insurance plans is setting off alarm bells among oncology leaders, who have joined medical associations from across the country in objecting to the revision.